Fluvoxamine treatment of a child with severe PDD: a single case study

Area of Science:

• Neuroscience
• Psychiatry
• Developmental Psychology

Background:

• Selective serotonin reuptake inhibitors (SSRIs) are increasingly reported as beneficial for autism and pervasive developmental disorders (PDDs).
• This study investigates the efficacy of fluvoxamine, an SSRI, in a pediatric case.
• Autism Spectrum Disorder (ASD) and PDDs present significant challenges in behavior and social interaction.

Observation:

• A single case study involved a 7-year-old Caucasian female diagnosed with severe pervasive developmental disorder.
• Fluvoxamine was administered to assess its impact on behavioral and social deficits.
• The study focused on observable changes in repetitive behaviors, anxiety, aggression, and social communication.

Findings:

• Fluvoxamine demonstrated significant effectiveness in reducing stereotypical, repetitive behaviors.
• The treatment led to a notable decrease in anxiety and aggression levels.
• Improvements were observed in prelinguistic communication and social interaction skills.

Implications:

• SSRI treatment, specifically with fluvoxamine, warrants consideration for the long-term habilitation of children with autism and PDDs.
• This case suggests a potential therapeutic role for fluvoxamine in managing core symptoms of ASD.
• Further research, including larger controlled trials, is essential to confirm the efficacy and safety of fluvoxamine for pediatric autism treatment.